Ascendis Pharma Secures Lucrative Royalty Deal with BioMarin for Yuviwel Sales
Ascendis Pharma’s 18% royalty deal with BioMarin on Yuviwel secures recurring revenue in key markets, boosting its biotech growth and rare‑disease presence.
2 minutes to read